初诊伴弥漫大B细胞成分的滤泡淋巴瘤患者的临床特征与结局
纳入国内11个医学中心2000至2020年1845例初诊滤泡淋巴瘤患者,筛选出146例(7.9%)伴弥漫大B细胞成分者进行回顾性分析。弥漫大B细胞成分≥50%者3级比例、Ki-67≥70%比例及PET-CT SUVmax≥13比例更高;总体5年无进展生存率为58.9%,5年总生存率为90.4%。
要点
- 146例(7.9%)初诊滤泡淋巴瘤伴弥漫大B细胞成分,中位年龄56岁,男79例(54.1%)。
- 弥漫大B细胞成分≥50%者较<50%者3级比例(94.3%对91.9%,P=0.010)、Ki-67≥70%比例(58.5%对32.9%,P=0.013)及SUVmax≥13比例(72.4%对46.3%,P=0.030)更高。
- POD24患者5年总生存率较非POD24患者下降(70.3%对98.5%,P<0.001)。
核心结论
- 伴弥漫大B细胞成分≥50%的滤泡淋巴瘤患者临床及病理特征更具侵袭性。
- CHOP或CHOP样±利妥昔单抗方案可以改善患者的临床疗效。
- 利妥昔单抗维持治疗不能使患者的无进展生存和总生存获益。
- 诱导治疗后未达到完全缓解是影响无进展生存的独立危险因素。
研究设计与样本
- 纳入国内11个医学中心2000至2020年间分级1至3a级、年龄≥18岁初诊滤泡淋巴瘤患者1845例,筛选伴弥漫大B细胞成分的患者。
- 回顾性分析患者的临床资料及生存数据,应用单因素及多因素分析筛选影响预后的因素。
主要发现
- 146例(7.9%)初诊滤泡淋巴瘤患者病理伴弥漫大B细胞成分,中位年龄56(25-83)岁,男79例(54.1%),127例患者病理提示弥漫大B细胞成分比例。
- 弥漫大B细胞成分≥50%患者较<50%患者有更高的3级比例(94.3%对91.9%,P=0.010)、Ki-67指数≥70%比例(58.5%对32.9%,P=0.013)及PET-CT的SUVmax≥13比例(72.4%对46.3%,P=0.030)。
- 所有患者均接受CHOP或CHOP样±利妥昔单抗方案化疗,总反应率为88.2%,完全缓解率为76.4%。
- 在不同比例弥漫大B细胞成分组中,诱导治疗后缓解率及治疗后2年内疾病进展发生率的差异均无统计学意义(P值均>0.05)。
- 总体预计5年无进展生存率为58.9%,5年总生存率为90.4%,POD24患者的5年总生存率较非POD24患者下降(70.3%对98.5%,P<0.001)。
关键数值与推荐
- 与利妥昔单抗不维持治疗相比,利妥昔单抗维持治疗不能使患者的5年无进展生存率获益(57.7%对58.8%,P=0.543),5年总生存率具有获益趋势,但差异无统计学意义(100%对87.8%,P=0.082)。
- 多因素分析显示,诱导治疗后未达到完全缓解是影响患者无进展生存的独立危险因素(P=0.006),而乳酸脱氢酶高于正常值是影响患者总生存的独立危险因素(P=0.031)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical features and survival of newly diagnosed follicular lymphoma (FL) patients with diffuse large B-cell lymphoma (DLBCL) component. Methods: 1845 newly diagnosed FL patients aged ≥ 18 years with grades 1-3a in 11 medical centers in China from 2000 to 2020 were included, and patients with DLBCL component were screened. The clinical data and survival data of the patients were retrospectively analyzed, and the prognostic factors were screened by univariate and multivariate analysis. Results: 146 patients (7.9% ) with newly diagnosed FL had DLBCL component. The median age was 56 (25-83) years, 79 males (54.1% ) . The pathology of 127 patients showed the proportion of DLBCL component. Patients were divided into two groups according to whether the proportion of DLBCL component was ≥ 50% . The study found that patients with DLBCL component ≥ 50% had higher grade 3 ratio (94.3% vs 91.9% , P=0.010) , Ki-67 index ≥ 70% ratio (58.5% vs 32.9% , P=0.013) and PET-CT SUVmax ≥ 13 ratio (72.4% vs 46.3% , P=0.030) than patients with DLBCL component<50% . All patients received CHOP or CHOP like ± rituximab chemotherapy. The overall response rate (ORR) was 88.2% , and the complete response (CR) rate was 76.4% . In the groups with different proportions of DLBCL component, there was no significant difference in the remission rate after induction treatment and the incidence of disease progression within 2 years after initiation of treatment (POD24) (P<0.05) . The overall estimated 5-year progression free survival (PFS) rate was 58.9% , and the 5-year overall survival (OS) rate was 90.4% . The 5-year OS rate of POD24 patients was lower than that of non POD24 patients (70.3% vs 98.5% , P<0.001) . Compared with non maintenance treatment of rituximab, maintenance treatment of rituximab could not benefit the 5-year PFS rate (57.7% vs 58.8% , P=0.543) , and the 5-year OS rate had a benefit trend, but the difference was not statistically significant (100% vs 87.8% , P=0.082) . Multivariate analysis showed that failure to reach CR after induction treatment was an independent risk factor for PFS (P=0.006) , while LDH higher than normal was an independent risk factor for OS (P=0.031) . Conclusion: FL patients with DLBCL component ≥50% have more invasive clinical and pathological features. CHOP/CHOP like ± rituximab regimen can improve the clinical efficacy of patients. Rituximab maintenance therapy can not benefit the PFS and OS of patients. Failure to reach CR after induction therapy was the independent unfavorable factor for PFS. 目的: 探索初诊伴弥漫大B细胞成分的滤泡淋巴瘤(FL)患者的临床特征及生存。 方法: 纳入国内11个医学中心2000-2020年间分级1~3a级、年龄≥18岁初诊FL患者1 845例,筛选伴弥漫大B细胞成分的患者。回顾性分析患者的临床资料及生存数据,应用单因素及多因素分析筛选影响预后的因素。 结果: 146例(7.9%)初诊FL患者病理伴弥漫大B细胞成分,中位年龄56(25~83)岁,男79例(54.1%)。127例患者病理提示弥漫大B细胞成分比例,依据弥漫大B细胞比例是否≥50%将患者分为2组。研究发现,弥漫大B细胞成分≥50%患者较弥漫大B细胞成分<50%患者有更高的3级比例(94.3%对91.9%,P=0.010)、Ki-67指数≥70%比例(58.5%对32.9%,P=0.013)及PET-CT的SUVmax≥13比例(72.4%对46.3%,P=0.030)。所有患者均接受CHOP或CHOP样±利妥昔单抗方案化疗,总反应率(ORR)为88.2%,完全缓解(CR)率为76.4%。在不同比例弥漫大B细胞成分组中,诱导治疗后缓解率及治疗后2年内疾病进展(POD24)发生率的差异均无统计学意义(P值均>0.05)。总体预计5年无进展生存(PFS)率为58.9%,5年总生存(OS)率为90.4%,POD24患者的5年OS率较非POD24患者下降(70.3%对98.5%,P<0.001)。与利妥昔单抗不维持治疗相比,利妥昔单抗维持治疗不能使患者的5年PFS率获益(57.7%对58.8%,P=0.543),5年OS率具有获益趋势,但差异无统计学意义(100%对87.8%,P=0.082)。多因素分析显示,诱导治疗后未达到CR是影响患者PFS的独立危险因素(P=0.006),而LDH高于正常值是影响患者OS的独立危险因素(P=0.031)。 结论: 伴弥漫大B细胞成分≥50%的FL患者,临床及病理特征更具侵袭性,CHOP/CHOP样±利妥昔单抗方案可以改善患者的临床疗效,利妥昔单抗维持治疗不能使患者的PFS和OS获益,诱导治疗后未达到CR是影响患者PFS的独立危险因素。.
引用
- Lin ZJ, Zha J, Yi SH, et al. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968587. doi:10.3760/cma.j.issn.0253-2727.2022.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。